Tirzepatide peptide dosing: what actually happens to your dose over time

You've just been approved: what that first pen actually is

Picture the scene. Your consultation is complete, the prescriber has reviewed your answers the same day, and a plain, unbranded box arrives via DPD with a tracking notification on your phone. Inside is your first KwikPen (set to 2.5 mg) and a Patient Information Leaflet that is worth reading before anything else. That 2.5 mg pen is not a placeholder. It is the formally licensed starting strength, specifically included in the titration schedule because tirzepatide's most common side effects (nausea, loose stools, indigestion) are dose-related. Beginning low means your gut has four weeks to adapt before anything changes.

Many people expect to feel dramatic effects immediately and are surprised when appetite shifts are subtle at first. That is normal. The 2.5 mg phase is your system's adjustment window, not the treatment's ceiling. Your prescriber will review progress before any dose increase; at nume (at our pharmacy) every repeat order receives a fresh clinical assessment, so increases are not automatic. If tolerability is good and clinical criteria are met, the next step is typically 5 mg after four weeks. The tirzepatide dosing page covers what each of those transitions involves in more detail.

One practical point the leaflet will reinforce: inject into your abdomen, thigh or upper arm, rotating the site each week. Store the pen in the fridge at 2–8 °C. For the exact room-temperature window if you need to travel, the SmPC on the eMC is the definitive source, our prescribers will not give you a number that might differ from the leaflet in your box.

The titration arc: why six strengths and not just two

Tirzepatide's six-rung UK schedule (2.5, 5, 7.5, 10, 12.5 and 15 mg) is designed so that no single step is a dramatic jump. Each increase is 2.5 mg, each interval is roughly four weeks, and the whole ladder from start to maximum maintenance takes around 20 weeks if every step is tolerated without issue. In practice, some people stay longer at a particular dose because of side effects, personal choice, or because their prescriber judges that more time is clinically appropriate. The published trial data reflect this: in SURMOUNT-1, involving thousands of adults with obesity, participants on 15 mg saw average body-weight reductions of around 20–21% over 72 weeks, figures cited directly in NICE's appraisal of tirzepatide (TA1026).

The dual GIP and GLP-1 receptor mechanism is what distinguishes tirzepatide from older GLP-1 medicines. By engaging both pathways, the medicine slows gastric emptying and promotes satiety through two separate signalling routes. Whether that translates into a meaningful clinical difference for you specifically is a question a prescriber can help you think through; if you want to read more about how it works at a molecular level, the tirzepatide peptide page goes into the receptor biology in more detail. There is more on the receptor mechanism on the GLP-1 peptide tirzepatide page.

It is also worth noting that 15 mg is a ceiling, not a universal target. Some people reach a dose that works well before the maximum and stay there. The goal is the highest tolerated dose that produces a meaningful clinical response, not the highest dose on the label.

Side effects across the dosing schedule, and when to get medical help

Gastrointestinal effects are the most commonly reported: nausea, vomiting, diarrhoea, constipation, reflux, and burping. They tend to cluster in the days after a new pen is started or a dose goes up, and for most people they ease within one to two weeks as the body adjusts. Fatigue, headache and dizziness are also reported. The NHS medicines page for tirzepatide lists the full side-effect profile with frequency data drawn from the clinical trials and post-marketing reports.

A small number of side effects warrant urgent attention regardless of how mild things have seemed up to that point. Severe, persistent stomach pain that reaches through to the back (with or without vomiting) needs same-day medical assessment because it can signal acute pancreatitis, which the MHRA highlighted in a 2026 Drug Safety Update for GLP-1 medicines. Symptoms of gallbladder problems (sudden pain in the upper right abdomen, fever, jaundice), signs of a serious allergic reaction, and significant dehydration from prolonged vomiting or diarrhoea all fall into the same category: get medical help rather than waiting for your next consultation. Report anything unexpected to the MHRA via the Yellow Card scheme, patient reports genuinely shape how the safety profile of newer medicines is understood over time.

If you are on oral contraceptives, your prescriber will advise adding a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide's effect on gastric emptying can reduce pill absorption during that window. That conversation should happen at consultation, not after the prescription arrives.

What eligibility and cost look like before you begin

The licensed eligibility criteria for tirzepatide in the UK are a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone never decides approval, the prescriber considers the full clinical picture, including medicines you already take and any conditions that might affect suitability.

On the NHS, access follows a phased rollout under NICE TA1026, with strict comorbidity and BMI thresholds that many people do not currently meet. Private treatment through a regulated online pharmacy is the route for people outside those criteria or who would rather not wait. Cost is a real consideration; the price changes that followed Eli Lilly's September 2025 list-price adjustment shifted what private treatment costs considerably, and it is worth understanding what a quoted price actually includes before committing. If you are weighing up your options and want a fuller picture of how peptides like tirzepatide fit into the broader range of weight-loss treatments available, the treatment page sets out what is covered at nume (sorry, at our weight-loss service) as one transparent figure: consultation, prescription, delivery and aftercare, with no subscription and no auto-renewal. If you want to check whether tirzepatide is likely to be clinically suitable for you, the first step is a free consultation.